Firms ally to create platform for immunotherapy production

03/27/2013 | Genetic Engineering & Biotechnology News · RTT News

Sanofi and Transgene will invest $12.9 million to create a new industrial platform for immunotherapy production. The platform will belong to Sanofi. Sanofi and Genzyme will use the platform to manufacture clinical and commercial batches of Transgene's MVA1 therapeutic vaccines and other immunotherapy products.

View Full Article in:

Genetic Engineering & Biotechnology News · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX